Skip to content
SEAJMS|ISSN: 2520-7342
Log in
SE
SEAJMS
Review ArticlePeer-reviewedOpen Access · CC BY-NC-SA 4.0

Diabetes Mellitus and Diverse Approaches to Its Management in Practical Application

Mohd Altaf Dar1, Zulfkar Qadrie2

  1. 1 Department of Pharmacology, CT Institute of Pharmaceutical Sciences, PTU, Jalandhar Punjab (corresponding author)
  2. 2 Senior Resident, Department of Pharmacology, Government Medical College Baramulla

Published 2024-01-15 · pp. 1-14

Download PDFXML

Abstract

Diabetes is a lifelong (chronic) disease and is a group of metabolic disorders characterized by high levels of sugar in blood (hyperglycemia). More than 230 million people worldwide are affected, and it is expected to reach 350 million by 2025. Globally the affected people are unaware of the disease and only half receive adequate treatment. It is caused due to deficiency of insulin or resistance to insulin or both. Insulin is secreted by β-cells of pancreas to control blood sugar levels. Advancing age, obesity and history of diabetes in the family have been identified as a major risk factors for diabetes in a study conducted by National Institute of Diabetes and Digestive and Kidney Diseases. Although not highly correlated, gender and lack of sufficient exercise were also found to be risk factors for diabetes. A life style intervention with weight loss, exercise regimen and diet control is often the first step in treatment of patients with newly diagnosed with diabetes and recommended by the ADA. The main goal of diabetes management is, as far as possible, to restore carbohydrate metabolism to a normal state. To achieve this goal, individuals with an absolute deficiency of insulin require insulin replacement therapy, which is given through injections or tablets. Insulin resistance, in contrast, can be corrected by dietary modifications and exercise.

Keywords: Diabetes Mellitus, insulin, hyperglycemia, oral hypoglycemic.

References

  1. Blair M. Diabetes Mellitus Review. Urol Nurs. 2016 Jan-Feb; 36(1):27-36. [Crossref] [Google Scholar]
  2. Lihite RJ, Lahkar M, Das S, Hazarika D, Kotni M, Maqbool M, Phukan S. A study on adverse drug reactions in a tertiary care hospital of Northeast India. Alexandria journal of medicine. 2017 Jul 11;53(2):151-6. [Crossref] [Google Scholar]
  3. Ribeiro C, de Alencar Mota CS, Voltarelli FA, de Araújo MB, Botezelli JD, et al. Effects of Moderate Intensity Physical Training in Neonatal Alloxan- Administered Rats. J Diabetes Metab. 2010; 1:107. [Crossref] [Google Scholar]
  4. Zehravi M, Maqbool M, Ara I. Polycystic ovary syndrome and infertility: an update. International journal of adolescent medicine and health. 2021 Jul 22;34(2):1-9. [Crossref] [Google Scholar]
  5. da Silva SB, Costa JP, Pintado ME, Ferreira DC, Sarmento B. Antioxidants in the Prevention and Treatment of Diabetic Retinopathy – A Review. J Diabetes Metab. 2010; 1:111. [Crossref] [Google Scholar]
  6. Zehravi M, Maqbool M, Ara I. Correlation between obesity, gestational diabetes mellitus, and pregnancy outcomes: an overview. International Journal of Adolescent Medicine and Health. 2021 Jun 18;33(6):339-45. [Crossref] [Google Scholar]
  7. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37 Suppl 1:S81–S90. [Crossref] [Google Scholar]
  8. Maqbool M, Bekele F, Fekadu G. Treatment strategies against triple-negative breast cancer: an updated review. Breast Cancer: Targets and Therapy. 2022 Jan 11:15-24. [Crossref] [Google Scholar]
  9. Craig ME, Hattersley A, Donaghue KC. Definition, epidemiology and classification of diabetes in children and adolescents. Pediatr Diabetes. 2009;10 Suppl 12:3–12. [Crossref] [Google Scholar]
  10. Rasool S, Maqbool M. An overview about Hedychium spicatum: a review. Journal of Drug Delivery and Therapeutics. 2019 Feb 15;9(1-s):476-80. [Crossref] [Google Scholar]
  11. Galtier F. Definition, epidemiology, risk factors. Diabetes Metab. 2010;36:628–651. [Crossref] [Google Scholar]
  12. Zehravi M, Maqbool M, Ara I. Depression and anxiety in women with polycystic ovarian syndrome: a literature survey. International Journal of Adolescent Medicine and Health. 2021 Aug 23;33(6):367-73. [Crossref] [Google Scholar]
  13. M.N. Piero, G.M. Nzaro, J.M. Njagi. Diabetes mellitus – a devastating metabolic disorder. Asian Journal of Biomedical and Pharmaceutical Sciences; 04 (40); 2014 ,1-7. [Crossref] [Google Scholar]
  14. Maqbool M, Gani I, Dar MA. Anti-diabetic effects of some medicinal plants in experimental animals: a review. Asian Journal of Pharmaceutical Research and Development. 2019 Feb 15;7(1):66-9. [Crossref] [Google Scholar]
  15. Deshmukh, C.D. and Jain, A. Int. J. Pure App. Biosci. 3 (3): 224-230 (2015) [Crossref] [Google Scholar]
  16. Zehravi M, Maqbool M, Ara I. Polycystic ovary syndrome and reproductive health of women: a curious association. International journal of adolescent medicine and health. 2021 Apr 21;33(6):333-7. [Crossref] [Google Scholar]
  17. Pittas AG (2009) Diabetes Mellitus, Diagnosis and Pathophysiology. Tufts University; 2005-2009. [Crossref] [Google Scholar]
  18. Mohd M, Maqbool M, Dar MA, Mushtaq I. Polycystic ovary syndrome, a modern epidemic: an overview. Journal of Drug Delivery and Therapeutics. 2019 May 15;9(3):641-4. [Crossref] [Google Scholar]
  19. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997; 20: 1183-97. [Crossref] [Google Scholar]
  20. Maqbool M, Fekadu G, Jiang X, Bekele F, Tolossa T, Turi E, Fetensa G, Fanta K. An up to date on clinical prospects and management of osteoarthritis. Annals of Medicine and Surgery. 2021 Dec 1;72:103077. [Crossref] [Google Scholar]
  21. World Health Organization Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia : Report of a WHO/IDF consultation. Geneva: WHO; 2006. [Crossref] [Google Scholar]
  22. Majeed A, Bashir R, Farooq S, Maqbool M. Preparation, characterization and applications of nanoemulsions: An insight. Journal of Drug Delivery and Therapeutics. 2019 Mar 15;9(2):520-7. [Crossref] [Google Scholar]
  23. American Diabetes Association. Position Statement. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009; 32: S62-S67. [Crossref] [Google Scholar]
  24. Zehravi M, Maqbool M, Ara I. Healthy lifestyle and dietary approaches to treating polycystic ovary syndrome: a review. Open Health. 2022 May 2;3(1):60-5. [Crossref] [Google Scholar]
  25. Kumar PJ, Clark M (2002) Textbook of Clinical Medicine. Pub: Saunders, London, UK. 1099-1121. [Crossref] [Google Scholar]
  26. Maqbool R, Maqbool M, Zehravi M, Ara I. Menstrual distress in females of reproductive age: a literature review. International journal of adolescent medicine and health. 2021 Jul 22;34(2):11-7. [Crossref] [Google Scholar]
  27. Baynes HW (2015) Classification, Pathophysiology, Diagnosis and Management of Diabetes Mellitus. J Diabetes Metab 6: 541. [Crossref] [Google Scholar]
  28. Malik JA, Maqbool M. COVID-19: An overview of current scenario. 셀메드. 2020 Aug;10(3):17-24. [Crossref] [Google Scholar]
  29. International Diabetes Federation. IDF Diabetes Atlas. 6th ed. Brussels, Belgium: International Diabetes Federation; 2013. [Crossref] [Google Scholar]
  30. Maqbool M, Rasool S, Dar MA, Bashir R, Khan M. Hepatotoxicity and Hepatoprotective agents: A Mini review. PharmaTutor. 2019 Sep 1;7(9):34-40. [Crossref] [Google Scholar]
  31. Akram T Kharroubi and Hisham M Darwish Diabetes mellitus: The epidemic of the century World J Diabetes. 2015 Jun 25; 6(6): 850–867. [Crossref] [Google Scholar]
  32. Ara I, Maqbool M, Fekadu G, Hajam TA, Dar MA. Pharmaceutical significance of Nigella sativa L., a wonder herb. Journal of Applied Pharmaceutical Sciences and Research. 2020;3(4):04-13. [Crossref] [Google Scholar]
  33. Bastaki, S., Review Diabetes mellitus and its treatment, Int J Diabetes & Metabolism, 13: 111-134 (2005) [Crossref] [Google Scholar]
  34. Maqbool M, Nasir N, Mustafa S. Polycystic in ovarian syndrome and its various treatment strategies. INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2018 Sep 1;5(9):8470-8. [Crossref] [Google Scholar]
  35. Harris MI. Epidemiological correlates of NIDDM in Hispanics, whites, and blacks in the U.S. population. Diabetes care. 1991;14(7):639. [Crossref] [Google Scholar]
  36. Maqbool M, Zehravi M, Maqbool R, Ara I. Study of adverse drug reactions in pulmonary medicine department of a Tertiary care hospital, Srinagar, Jammu & Kashmir, India. CELLMED. 2021;11(2):8-1. [Crossref] [Google Scholar]
  37. Pories WJ, Swanson MS, MacDonald KG. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Annals of Surgery. Sep 1995;222(3):339-352. [Crossref] [Google Scholar]
  38. Ara I, Maqbool M, Bukhari B, Ara N, Hajam TA. Present status, standardization and safety issues with herbal drugs. International Journal of Research in Pharmaceutical Sciences and Technology. 2020 May 18;1(3):95-101. [Crossref] [Google Scholar]
  39. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery. New England Journal of Medicine. 2004;351(26):2683-2693. [Crossref] [Google Scholar]
  40. Maqbool M, Fekadu G, Dugassa D, Bekele F, Turi E, Simegnew D. The pattern of substance abuse in the psychiatry department of a tertiary care of Srinagar hospital, Jammu and Kashmir, India. Archives of Neuroscience. 2020 Oct 31;7(4). [Crossref] [Google Scholar]
  41. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. Aug 2006;49(8):1711-1721. [Crossref] [Google Scholar]
  42. Maqbool M, Dar AM, Rasool S, Khan M. Curious case of drug resistant malaria and artemisinin compounds in the modern era. Journal of Applied Pharmaceutical Sciences and Research. 2019 Jul 8:1-4. [Crossref] [Google Scholar]
  43. Impact of Intensive Lifestyle and Metformin Therapy on Cardiovascular Disease Risk Factors in the Diabetes Prevention Program. Diabetes Care. April 1, 2005 2005;28(4):888-894. [Crossref] [Google Scholar]
  44. Ara I, Maqbool M, Gani I. Reproductive Health of Women: implications and attributes. International Journal of Current Research in Physiology and Pharmacology. 2022 Nov 28:8-18. [Crossref] [Google Scholar]
  45. Hadden DR, Montgomery DAD, Skelly RJ, et al. Maturity Onset Diabetes Mellitus: Response To Intensive Dietary Management. The British Medical Journal. 08/021975;3(5978):276-278. [Crossref] [Google Scholar]
  46. Zehravi M, Maqbool R, Maqbool M, Ara I. To Identify Patterns of Drug Usage among Patients Who Seek Care in Psychiatry Outpatient Department of a Tertiary Care Hospital in Srinagar, Jammu and Kashmir, India. Journal of Pharmaceutical Research International. 2021 Jun 10;33(31A):135-40. [Crossref] [Google Scholar]
  47. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus.Drugs. 2005;65(3):385-411. [Crossref] [Google Scholar]
  48. Fekadu G, Bekele F, Bekele K, Hanbisa S, Belay G, Maqbool M. Drug use evaluation of beta-blockers in medical wards of Nedjo general hospital, Western Ethiopia. Cardiovascular Therapeutics. 2020 Jun 1;2020. [Crossref] [Google Scholar]
  49. Bailey CJ, Turner RC. Metformin. New England Journal of Medicine. 1996;334:574-579. [Crossref] [Google Scholar]
  50. Maqbool M, Javed S, Bajwa AA. Assessment OF pain management IN postoperative cases using different scales and questionnaires. INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2019 Jan 1;6(1):983-7. [Crossref] [Google Scholar]
  51. Foye WO, Lemke TL, Williams DA. Foye's Principles of Medicinal Chemistry. Sixth ed:Wolters Kluwer; 2008. [Crossref] [Google Scholar]
  52. Ara I, Maqbool M, Zehravi M. Psychic consequences of infertility on couples: A short commentary. Open Health. 2022 Jan 1;3(1):114-9. [Crossref] [Google Scholar]
  53. Souhami RL, Moxham J. Textbook of medicine. Third ed. London: Churchill Liingstone; 1997. [Crossref] [Google Scholar]
  54. Maqbool M, Dugassa D, Fekadu G. Adverse drug reactions of antiepileptic drugs in the neurology department of a tertiary care hospital, Srinagar, Jammu & Kashmir, India. Archives of Neuroscience. 2021 Apr 30;8(2). [Crossref] [Google Scholar]
  55. Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention.Drug Safety. Sep 1 2010;33(9):727-740. [Crossref] [Google Scholar]
  56. Bashir R, Maqbool M, Ara I, Zehravi M. An In sight into Novel Drug Delivery System: In Situ Gels. CELLMED. 2021;11(1):6-1. [Crossref] [Google Scholar]
  57. Zangeneh F, Kudva YC, Basu A. Insulin sensitizers. Mayo Clin Proc. 2003;78:471-479. [Crossref] [Google Scholar]
  58. Zehravi M, Maqbool M, Ara I. Teenage menstrual dysfunction: an overview. International Journal of Adolescent Medicine and Health. 2022 Sep 19;35(1):15-9. [Crossref] [Google Scholar]
  59. Rendell M. The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus. Drugs. 2004;64(12):1339-1358. [Crossref] [Google Scholar]
  60. Dar MA, Maqbool M, Rasool S. Pharmaceutical wastes and their disposal practice in routine. Int J Inf Comput Sci. 2019 Apr;6:76-92. [Crossref] [Google Scholar]
  61. Rasool S, Maqbool M, Joshi Y. Drug utilization studies among ENT patients in various clinical settings: A comprehensive review. Journal of Drug Delivery and Therapeutics. 2019 Feb 15;9(1-s):481-5. [Crossref] [Google Scholar]
  62. Krentz AJ, Bailey CJ, Melander A. Thiazolidinediones for type 2 diabetes. British Medical Journal. 2000;321:252-253. [Crossref] [Google Scholar]
  63. Ara I, Zehravi M, Maqbool M, Gani I. A review of recent developments and future challenges in the implementation of universal health coverage policy framework in some countries. Journal of Pharmaceutical Research & Reports. SRC/JPRSR-131. DOI: doi. org/10.47363/JPRSR/2022 (3). 2022;127. [Crossref] [Google Scholar]
  64. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabetic Medicine. 1999;16:1-14. 70. [Crossref] [Google Scholar]
  65. Maqbool M, Dar MA, Rasool S, Gani I, Khan M. Substance use disorder and availability of treatment options: an overview. Journal of research in health science. 2019;1:4-10. [Crossref] [Google Scholar]
  66. Yki-Jarvinen H. Thiazolidinedions. New England Journal of Medicine. 2004;351:1106- 1118. [Crossref] [Google Scholar]
  67. Maqbool M, Shabbir W, Aamir S. Adverse events of blood transfusion and blood safety in clinical practice. Indo American Journal Of Pharmaceutical Sciences. 2018 Aug 1;5(8):8254-9. [Crossref] [Google Scholar]
  68. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and the American Diabetes Association. Circulation. 2003;108:2941-2948. [Crossref] [Google Scholar]
  69. Maqbool M, Naeem A, Aamer S. Diabetes mellitus and its various management strategies in practice. Indo American Journal of Pharmaceutical Sciences. 2018 Aug 1;5(8):8163-+. [Crossref] [Google Scholar]
  70. Nathan DM BJ, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care.2008;31(12):1-11. [Crossref] [Google Scholar]
  71. Maqbool M, Tariq S, Amjad S. Prescribing practices in pediatrics and drug utilization studies promoting pediatric health. Indo American Journal of Pharmaceutical Sciences. 2018 Aug 1;5(8):8070-6. [Crossref] [Google Scholar]
  72. Van de Laar FA, Lucassen PL, Akkermans RP. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev CD003639. 2005. [Crossref] [Google Scholar]
  73. Maqbool M, Ikram U, Anwar A. Adverse drug reaction monitoring and occurrence in drugs used in pulmonary disorders. Indo American Journal Of Pharmaceutical Sciences. 2018 Aug 1;5(8):8060-5. [Crossref] [Google Scholar]
  74. Kristensen JS, Frandsen KB, Bayer T, Muller PG. Compared with repaglinide, sulfonylurea treatment in type 2 diabetes is associated with a 2.5 fold increase in symptomatic hypoglycemia with blood glucose levels <45 mg/dl. Diabetes 2000; 49 (Suppl 1):A131 (Abstract). [Crossref] [Google Scholar]
  75. Maqbool R, Maqbool M, Zehravi M, Ara I. Acute neurological conditions during pregnancy and their management: a review. International Journal of Adolescent Medicine and Health. 2021 Aug 23;33(6):357-66. [Crossref] [Google Scholar]
  76. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083–1091. [Crossref] [Google Scholar]
  77. Maqbool M, Zehravi M, Maqbool R, Ara I. An overview about treatment of gestational diabetes mellitus: A short communication. CELLMED. 2021;11(3):12-. [Crossref] [Google Scholar]
  78. DeFronzo R, Ratner RE, Han J, et al. Effects of exenatide on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care.2005;28:1092–1100. [Crossref] [Google Scholar]
  79. Fekadu G, Gamachu B, Mengie T, Maqbool M. Knowledge, attitude of health care professional’s towards clinical pharmacy services in Nedjo General Hospital, Western Ethiopia. International Journal. 2019 Jul;5(7):172. [Crossref] [Google Scholar]
  80. Buse JB, Henry RR, Han J, et al. Exenatide-113 Clinical Study Group (2004) Effects of exenatide on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628–2635. [Crossref] [Google Scholar]
  81. Maqbool M. Evaluation of drug utilization pattern in the pediatric department of a Tertiary Care Hospital in Srinagar, Jammu & Kashmir, India. Journal of Applied Pharmaceutical Sciences and Research. 2019:6-9. [Crossref] [Google Scholar]
  82. Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. International Journal of Clinical Practice. 2007;61:171–180. [Crossref] [Google Scholar]
  83. Maqbool M, Gani I. Utilization of statins in reducing comorbidities of diabetes mellitus: A systematic review. Journal of Pharmacy Practice and Community Medicine. 2018;4(4). [Crossref] [Google Scholar]
  84. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia.2006;49:2564–2571. [Crossref] [Google Scholar]
  85. Maqbool M, Ara I, Gani I. The Story of Polycystic Ovarian Syndrome: A Challenging Disorder with Numerous Consequences for Females of Reproductive Age. International Journal of Current Research in Physiology and Pharmacology. 2022 Nov 28:19-31. [Crossref] [Google Scholar]
  86. Aschner P, Kipnes MS, Lunceford JK. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29:2632–2637. [Crossref] [Google Scholar]
  87. Maqbool M, Zehravi M. Neuroprotective role of polyphenols in treatment of neurological disorders: A review. Interventional Pain Medicine and Neuromodulation. 2021 Dec 31;1(1). [Crossref] [Google Scholar]
  88. Miller, Onje ELS, Taylor J. DPP-IV inhibitors: A review of sitagliptin, vildagliptin, alogliptin, and saxagliptin. Formulary. April 2008;43(4). [Crossref] [Google Scholar]
  89. Maqbool M, Arshad B, Liaquat S. Psychotropic drug utilisation pattern can be useful in monitoring treatment regimens for mental disorders in psychiatric settings. INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2018 Aug 1;5(8):7717-21. [Crossref] [Google Scholar]
  90. Schmitz O, Brock B, Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes Care. 2004;53 (Suppl 3):S233–S238. [Crossref] [Google Scholar]
  91. Zehravi M, Maqbool M, Ara I. Unfolding the mystery of premenstrual syndrome (PMS): an overview. International Journal of Adolescent Medicine and Health. 2022 Sep 19;35(1):9-13. [Crossref] [Google Scholar]
  92. Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes. Diabetes Care. 2003;26:784–790. [Crossref] [Google Scholar]
  93. Zehravi M, Maqbool M, Ara I. An overview about safety surveillance of adverse drug reactions and pharmacovigilance in India. The Indian Journal of Nutrition and Dietetics. 2021 Jul:408-18. [Crossref] [Google Scholar]
  94. Ryan GJ, Jobe LJ, Martin R. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clinical Therapeutics. 2005;27:1500-1512. [Crossref] [Google Scholar]
  95. Ara I, Kalam MA, Maqbool M, Zehravi M. Phytochemical Standardization and Anti-Anxiety (Izterab-e-Nafsani) study of Aftimoon Hindi (Cuscuta reflexa Roxb.) on An Animal Model. CELLMED. 2021;11(3):14-. [Crossref] [Google Scholar]
  96. Thayer A. Insulin. Chemical Engineering News. Vol 83; 2005:74-75. [Crossref] [Google Scholar]
  97. Maqbool M, Khan M. Hypertension and Pregnancy: an important issue. PharmaTutor. 2019 Aug 1;7(8):71-8. [Crossref] [Google Scholar]
  98. Briscoe VJ, Davis SN. Hypoglycemia in Type 1 and Type 2 Diabetes:Physiology, Pathophysiology, and Management. Clinical Diabetes. 2006;24(3):115-121. [Crossref] [Google Scholar]
  99. Ara I, Maqbool M, Gani I. Neuroprotective Activity of Herbal Medicinal Products: A Review. International Journal of Current Research in Physiology and Pharmacology. 2022 Dec 23:1-0. [Crossref] [Google Scholar]
  100. Zammitt NN, Frier BM. Hypoglycemia in Type 2 Diabetes: Pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care. December 2005;28(12):2948-2961. [Crossref] [Google Scholar]
  101. Dar MA, Maqbool M, Javed S. Assessing Health-Related Quality Of Life (Qol) In Rheumatoid Arthritis. INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2019 Jan 1;6(1):988-94. [Crossref] [Google Scholar]
  102. Dar MA, Maqbool M, Gani I, Ara I. Menstruation hygiene and related issues in adolescent girls: A brief commentary. International Journal of Current Research in Physiology and Pharmacology. 2023 Feb 11:1-5. [Crossref] [Google Scholar]
  103. Ara I, Maqbool M. The curious case of Neuropathic Pain and its management: an overview. Open Health. 2022 Oct 17;3(1):145-54. [Crossref] [Google Scholar]
  104. Zehravi M, Maqbool M, Ara I. An Update on Pain Control in Conservative Dentistry and Endodontics: A Review. The Indian Journal of Nutrition and Dietetics. 2022 Jan:114-25. [Crossref] [Google Scholar]
  105. Ara I, Maqbool M, Zehravi M, Gani I. Herbs Boosting Immunity in Covid-19: An Overview. Adv J Chem B. 2020;3(3):289-94. [Crossref] [Google Scholar]